News

Orkambi wins CHMP’s thumbs-up for children ages 1 to 2

Vertex Pharmaceuticals has received a positive opinion from an arm of the European Medicines Agency on expanding the use of Orkambi (lumacaftor/ivacaftor) to children ages 1-2 who have two copies of the F508del mutation, the most common genetic defect in cystic fibrosis (CF). With the recommendation from…

Cystic Fibrosis Awareness Month is all about sharing

From sharing personal stories to switching out Facebook cover photos, there are a variety of ways to participate in Cystic Fibrosis (CF) Awareness Month, set aside each May to acknowledge the CF community and call attention to its needs. CF is a genetic disease thought to affect some…

Rare CFTR-active airway cell grown from CF patients

A rare cell type that lines the airways, called pulmonary ionocytes, was successfully generated from stem cells derived from people with cystic fibrosis (CF), a study reports. Among all the cell types that line the airways, the recently discovered ionocytes, which make up about 1% of cells, have the…

Sale of wound care platform will benefit CF research

30 Technology has sold the rights to its antimicrobial treatment platform for certain uses, such as for burns and acute wounds, to Convatec. 30 Technology will retain the rights to its wound care platform in other indications, including respiratory diseases such as cystic fibrosis (CF), and will be…